Angio-Long Noncoding RNA MALAT1 (rs3200401) and MIAT (rs1061540) Gene Variants in Ovarian Cancer
Authors:
- Manal S. FawzyManal S. Fawzy
- Afaf T. IbrahiemAIAfaf T. Ibrahiem
- Dalia Mohammad OsmanDODalia Mohammad Osman
- Amany I. AlmarsAAAmany I. Almars
- Maali Subhi AlshammariMAMaali Subhi Alshammari
- Layan Tariq AlmazyadLALayan Tariq Almazyad
- Noof Daif Allah AlmatrafiNANoof Daif Allah Almatrafi
- Renad Tariq AlmazyadRARenad Tariq Almazyad
- Eman A. ToraihEman A. Toraih
Open Access
- 29 January 2024
- journal article
- research article
- Published by MDPI AG in Epigenomes
- Vol. 8 (1) , 5
Abstract
The genotyping of long non-coding RNA (lncRNA)-related single-nucleotide polymorphisms (SNPs) could be associated with cancer risk and/or progression. This study aimed to analyze the angiogenesis-related lncRNAs MALAT1 (rs3200401) and MIAT (rs1061540) variants in patients with ovarian cancer (OC) using “Real-Time allelic discrimination polymerase chain reaction” in 182 formalin-fixed paraffin-embedded (FFPE) samples of benign, borderline, and primary malignant ovarian tissues. Differences in the genotype frequencies between low-grade ovarian epithelial tumors (benign/borderline) and malignant tumors and between high-grade malignant epithelial tumors and malignant epithelial tumors other than high-grade serous carcinomas were compared. Odds ratios (ORs)/95% confidence intervals were calculated as measures of the association strength. Additionally, associations of the genotypes with the available pathological data were analyzed. The heterozygosity of MALAT1 rs3200401 was the most common genotype (47.8%), followed by C/C (36.3%). Comparing the study groups, no significant differences were observed regarding this variant. In contrast, the malignant epithelial tumors had a higher frequency of the MIAT rs1061540 C/C genotype compared to the low-grade epithelial tumor cohorts (56.7% vs. 37.6, p = 0.031). The same genotype was significantly higher in high-grade serous carcinoma than its counterparts (69.4% vs. 43.8%, p = 0.038). Multivariate Cox regression analysis showed that the age at diagnosis was significantly associated with the risk of OC development. In contrast, the MIAT T/T genotype was associated with a low risk of malignant epithelial tumors under the homozygote comparison model (OR = 0.37 (0.16–0.83), p = 0.017). Also, MIAT T allele carriers were less likely to develop high-grade serous carcinoma under heterozygote (CT vs. CC; OR = 0.33 (0.12–0.88), p = 0.027) and homozygote (TT vs. CC; OR = 0.26 (0.07–0.90), p = 0.034) comparison models. In conclusion, our data provide novel evidence for a potential association between the lncRNA MIAT rs1061540 and the malignant condition of ovarian cancer, suggesting the involvement of such lncRNAs in OC development.Keywords
Funding Information
- Northern Borders University (MEDA-2022-11-1742)
This publication has 87 references indexed in Scilit:
- Hereditary Ovarian Cancer: Not OnlyBRCA1 and 2 GenesBioMed Research International, 2015
- lncRNA-MIAT Regulates Microvascular Dysfunction by Functioning as a Competing Endogenous RNACirculation Research, 2015
- Whole exome sequencing of a single osteosarcoma case—integrative analysis with whole transcriptome RNA-seq dataHuman Genomics, 2014
- Long Noncoding RNA MALAT1 Regulates Endothelial Cell Function and Vessel GrowthCirculation Research, 2014
- Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of colorectal cancerJournal of Experimental & Clinical Cancer Research, 2013
- Comprehensive Analysis of Long Non-Coding RNAs in Ovarian Cancer Reveals Global Patterns and Targeted DNA AmplificationPLOS ONE, 2013
- Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31Nature Communications, 2013
- Clinical Relevance of KRAS in Human CancersJournal of Biomedicine and Biotechnology, 2010
- The Contribution of BRCA1 and BRCA2 to Ovarian CancerMolecular Oncology, 2009
- KRAS and BRAF mutations in ovarian tumors: A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implantsGynecologic Oncology, 2006